Effect of Noncytotoxic Second-Line Regimen for Metastatic Pancreatic Cancer

This phase 2 randomized clinical trial compares selumetinib and MK-2206 vs modified FOLFOX chemotherapy in patients with metastatic pancreatic cancer for whom gemcitabine-based therapy had failed.

http://ift.tt/2gQ46u5